Incidence of Anemia in Children With Solid Tumors or Hodgkin Disease

Hockenberry, Marilyn J.; Hinds, Pamela S.; Barrera, Patrick; Billups, Catherine A.; Rodríguez‐Galindo, Carlos; Tan, M. Eunice Rigor; Kline, Nancy E.; Razzouk, Bassem I.

doi:10.1097/00043426-200201000-00010

Cited by 11 publications

(6 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Anemia is a potential contributor to the functional impairment that often occurs during and after chemotherapy. Among children with malignant solid tumors, and particularly among children with NB, a significant proportion (51–74%) experience anemia at diagnosis35 and during treatment. Anemia is associated with a significant impairment in quality of life caused by fatigue.…”

Section: Discussionmentioning

confidence: 99%

Expression of erythropoietin and its receptor in neuroblastomas

Sartelet

Fabrè

Castaing

et al. 2007

Cancer

View full text Add to dashboard Cite

BACKGROUND. Children with high‐risk neuroblastomas (NB) potentially may benefit from treatment with recombinant human erythropoietin (Epo). Epo is a stimulator of erythropoiesis, acting through its receptor (EpoR). The objective of the current study was to evaluate expression levels of Epo and EpoR in NB and in normal tissues and their effects on the proliferation of tumor cells. METHODS. A tissue microarray study was performed with 101 primary tumors, 39 paired metastases, 56 paired control tissues, and 6 human NB cell lines. Immunohistochemical staining was performed using antibodies against Epo and EpoR. Immunostaining intensity was evaluated by using a semiquantitative score based on the percentage of positive cells. An in vitro analysis of cell proliferation and cell cycle in the presence of recombinant Epo was performed in the 6 cell lines. RESULTS. The expression of EpoR was found to be significantly higher in tumors than in paired control tissues (P < .0001) compared with the expression of Epo (P = .06), and the expression of EpoR was significantly higher in lymph node metastases than in paired primary tumors (P = .02) compared with Epo (P = .99). Survival analysis demonstrated that the patients who had tumors with the highest expression of EpoR had a significantly better overall survival (P = .03). In the in vitro study, recombinant Epo did not modify proliferation and cell cycle in the cell lines regardless of the EpoR expression level. CONCLUSIONS. Epo and EpoR were expressed in NB but did not modify tumor cell proliferation. The results of the current study suggested that Epo may be used safely for supportive care in children with NB. Cancer 2007. © 2007 American Cancer Society.

show abstract

Section: Discussionmentioning

confidence: 99%

Expression of erythropoietin and its receptor in neuroblastomas

Sartelet

Fabrè

Castaing

et al. 2007

Cancer

View full text Add to dashboard Cite

show abstract

“…The incidence of anemia in a large sample of children and adolescents with newly diagnosed Hodgkin's disease or a solid tumor was more than 50%, but data about the incidence of anemia in other diagnoses or over the course of treatment were not reported (Hockenberry et al, 2002). In another large sample of children and adolescents with a variety of new cancer diagnoses, fatigue was correlated with other symptoms, such as anorexia, weight loss, and early satiety at the time of diagnosis (Donaldson et al, 1981).…”

Section: Symptoms In Adolescents With Cancermentioning

confidence: 94%

“…Four were retrospective studies (Donaldson et al, 1981;Hockenberry et al, 2002;Novakovic et al, 1996;Wolfe et al, 2000).…”

Section: Symptoms In Adolescents With Cancermentioning

confidence: 99%

Fatigue in Adolescents With Cancer: A Review of the Literature

Erickson¹

2004

Clinical Journal of Oncology Nursing

View full text Add to dashboard Cite

Fatigue is a prevalent and distressing symptom in people with cancer, and adolescents with cancer are no exception. Research on fatigue in the context of age and development will help in the development of age-specific prevention and management guidelines. The developmental profile, cancer epidemiology, and research needs related to adolescents with cancer are unique. A number of descriptive studies now form the foundation of scientific knowledge about cancer-related fatigue in adolescents. From this research, a definition of fatigue has been constructed and age-specific instruments have been developed. In addition, several correlates and interventions have been proposed for future testing. This article reviews relevant literature related to the symptom of fatigue in adolescents with cancer, discusses future research directions, and recommends clinical strategies for management of fatigue in this population.

show abstract

“…Anemia in patients with leukemia is most often due to underproduction of erythropoietic precursors, because of direct tumor infiltration of the bone marrow or chemotherapies [6]. In patients undergoing HSCT, radiotherapy and preparative myeloablative chemotherapy regimens further challenge RBC precursor production.…”

Section: Pathophysiology Of Anemia In Patients With Malignant Hematolmentioning

confidence: 99%

Transfusions for anemia in adult and pediatric patients with malignancies

2015

View full text Add to dashboard Cite

Anemia is present in over two-thirds of patients with malignant hematological disorders. The etiology of anemia predominates from ineffective erythropoiesis from marrow infiltration, cytokine related suppression, erythropoietin suppression, and vitamin deficiency; ineffective erythropoiesis is further exacerbated by accelerated clearance due to antibody mediated hemolysis and thrombotic microangiopathy. As the anemia is chronic in nature, symptoms are generally well tolerated and often non-specific. Transfusion of red blood cells (RBCs) is a balance between providing benefit for patients while avoiding risks of transfusion. Conservative/restrictive RBC transfusion practices have shown equivalent patient outcomes compared to liberal transfusion practices, and meta-analysis has shown improved in-hospital mortality, reduced cardiac events, re-bleeding, and bacterial infections. The implications for a lower threshold for transfusion in patients with malignancies are therefore increasingly being scrutinized. Alternative management strategies for anemia with IV iron and erythropoietin stimulating agents (ESAs) should be considered in the appropriate settings.

show abstract

Incidence of Anemia in Children With Solid Tumors or Hodgkin Disease

Cited by 11 publications

References 18 publications

Expression of erythropoietin and its receptor in neuroblastomas

Expression of erythropoietin and its receptor in neuroblastomas

Fatigue in Adolescents With Cancer: A Review of the Literature

Transfusions for anemia in adult and pediatric patients with malignancies

Contact Info

Product

Resources

About